- Home
- NXRT vs AQST Comparison
NXRT vs AQST Comparison
Compare NXRT & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXRT | AQST |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.2M | 504.0M |
| IPO Year | 2014 | 2007 |
Fundamental Metrics
Financial Performance| Metric | NXRT | AQST |
|---|---|---|
| Price | $28.98 | $4.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.00 | $9.00 |
| AVG Volume (30 Days) | 153.3K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,281,000.00 | $67,430,000.00 |
| Revenue This Year | $3.09 | $10.08 |
| Revenue Next Year | $3.02 | $49.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $23.79 | $2.22 |
| 52 Week High | $38.08 | $7.55 |
Technical Indicators
Market Signals| Indicator | NXRT | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 66.30 | 55.89 |
| Support Level | $27.69 | $3.70 |
| Resistance Level | $32.12 | $4.35 |
| Average True Range (ATR) | 0.82 | 0.14 |
| MACD | 0.35 | -0.00 |
| Stochastic Oscillator | 89.06 | 55.56 |
Price Performance
Historical ComparisonAbout NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. The trust's objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.